MRK Gains FDA Approval for KEYTRUDA®—Big Opportunity!

Keytruda’s New Approval and Business Overview

Merck & Co. (NYSE: MRK) has secured an important FDA approval for its blockbuster immunotherapy KEYTRUDA® (pembrolizumab) as a first-line treatment (with chemotherapy) for advanced or recurrent endometrial carcinoma (www.fiercepharma.com). This marks Keytruda’s 40th U.S. approved indication and notably the first broad label immunotherapy for this cancer, leapfrogging a rival PD-1 drug (GSK’s Jemperli) that was limited to a narrower patient subset (www.fiercepharma.com). The new indication underscores Keytruda’s growth potential and reinforces Merck’s leadership in oncology, as Keytruda is already the world’s best-selling medicine with $25 billion in global sales in 2023 (www.fiercepharma.com).

Keytruda is absolutely central to Merck’s business today. In 2024, Keytruda generated $29.5 billion in revenue (up from $25.0B in 2023) – nearly half of Merck’s $57.4B pharmaceutical sales (www.sec.gov). Total company revenue was $64.2B in 2024, so a single drug contributed ~46% of sales (www.sec.gov). This heavy reliance on one product is a double-edged sword: Keytruda’s success has driven Merck’s growth, but it also means any expansion of Keytruda’s market (like this FDA approval) is a big opportunity for near-term gains. The endometrial cancer approval should add incremental revenue and patient reach, helping Merck maximize Keytruda’s potential in the remaining years before patent expiry. At the same time, Merck has been diversifying its portfolio and pipeline to prepare for the day when Keytruda eventually faces competition.

Dividend Policy & Shareholder Returns

Merck is known for a solid and rising dividend. The company has increased its dividend at a steady mid-single-digit pace in recent years. Annual dividends per share rose from $2.80 to $2.96 to $3.12 in 2021, 2022, and 2023 respectively (www.sec.gov). In dollar terms, Merck paid out $7.8 billion in dividends in 2024 (up from $7.4B in 2023 and $7.0B in 2022) (www.sec.gov). At current share prices, the dividend yield is roughly in the 2.8–3.5% range (varying with stock fluctuations), offering investors a meaningful income stream. Merck’s dividend is well-covered by cash flow – in 2024 the company generated $21.5B in operating cash flow (www.sec.gov), which comfortably exceeded the $7.8B of cash dividends paid (www.sec.gov). This implies a conservative payout ratio and room for continued dividend growth. Notably, Merck also engages in share buybacks opportunistically (about $1.3B repurchased in 2024) (www.sec.gov), but the dividend remains the primary vehicle of returning cash to shareholders. Overall, Merck’s dividend track record and coverage suggest a shareholder-friendly capital return policy, supported by stable underlying cash generation.

Leverage, Debt Maturities & Coverage

Merck’s balance sheet is strong, with moderate leverage and well-staggered debt maturities. As of year-end 2024, Merck had about $37.1 billion in total debt outstanding (www.sec.gov). The company also held a sizable cash balance of $13.2B (www.sec.gov), bringing net debt down to roughly $24B. This net debt is only about 1× Merck’s annual cash flow (2024 operating cash flow was $21.5B) (www.sec.gov), indicating modest leverage. Merck’s debt maturity profile is very manageable – over the next five years (2025–2029) only about $10.1B of long-term debt comes due, with no single year seeing more than ~$2.6B in maturities (www.sec.gov). For example, Merck has ~$2.6B due in 2025, $2.2B in 2026, $1.5B in 2027, etc., which should be easy to refinance or repay given its cash generation (www.sec.gov).

Interest expense is also well covered. Merck’s interest cost in 2024 was about $1.27 billion (www.sec.gov), whereas EBIT and operating cash flow are on the order of ~$17–21B, so interest coverage is extremely robust (15×–17× coverage by cash flow). The company’s credit ratings sit in the high investment-grade tier (around A+/Aa3), reflecting its strong cash flows and prudent balance sheet management. With low-cost debt and incremental financing capacity, Merck has flexibility to fund R&D or acquisitions without jeopardizing its dividend or core financial stability. Overall, leverage is not a red flag for Merck – debt levels are reasonable relative to earnings, and upcoming maturities are staggered and modest, reducing refinancing risk.

Valuation and Growth Outlook

Merck’s stock valuation appears attractive relative to its fundamentals, especially considering the growth opportunities ahead. At around mid-2025, MRK shares traded near the $80 level, which equated to only about 3.2× trailing revenues (www.nasdaq.com) and roughly 11–12× earnings. This is below Merck’s historical average (e.g. a 4.4× price-to-sales typical in recent years) (www.nasdaq.com) and below many large pharma peers. The market’s cautious view is largely due to the looming 2028 patent cliff for Keytruda and some near-term headwinds (for instance, a temporary Gardasil sales slowdown in China) (www.nasdaq.com). In other words, investors have “priced in” a slowdown, compressing Merck’s multiples.

There is upside potential if Merck can execute well. Analysts see room for valuation expansion once uncertainty over Keytruda’s replacement pipeline abates. For example, returning to a normal P/S multiple near 4.4× could imply Merck stock over $110 (~40% upside) from the $80s (www.nasdaq.com). The company’s own growth outlook is optimistic: Merck forecasts over $70 billion in annual revenue opportunities by the mid-2030s from new products and pipeline prospects (www.fiercepharma.com). (For context, $70B is more than double what Keytruda is expected to peak at in 2028 (~$35B) (www.fiercepharma.com).) Achieving this would mean Merck not only replaces Keytruda’s contribution but significantly grows beyond it. Key growth drivers include recently launched or upcoming products – for instance, Merck’s new 21-valent pneumococcal vaccine (branded Capvaxive) approved in 2024, and Winrevair (sotatercept for pulmonary hypertension) launched in 2024 via the Acceleron acquisition, are already contributing hundreds of millions in early sales (www.nasdaq.com). If such products continue to ramp up and pipeline candidates succeed, Merck’s earnings could re-accelerate in the late 2020s, supporting a higher stock valuation. For now, Merck trades at a discount to the pharma sector averages, but this discount could narrow if the company demonstrates clear progress in reducing its post-Keytruda revenue gap.

Risks and Red Flags

Despite Merck’s strengths, investors should keep in mind several risks and potential red flags:

- Keytruda Concentration & Patent Cliff (2028) – Merck’s biggest risk is the heavy reliance on Keytruda, which exceeds 45% of total sales (www.sec.gov). The drug’s main U.S. patent expires in 2028, and a flood of biosimilar competition is expected thereafter (www.fiercepharma.com). Management has indicated it has additional Keytruda patents extending to 2029 and will defend them (www.fiercepharma.com), but effectively by 2028-29 the franchise could see a steep decline. Any hiccup before then – such as a new competing therapy or unforeseen safety issue – could severely impact Merck’s revenues. This single-product concentration is a glaring vulnerability.

- Pipeline Execution & Acquisition Risks – Merck’s strategy to bridge the Keytruda gap leans heavily on pipeline success (20+ late-stage programs) and acquired assets. The company spent billions on acquisitions like Prometheus Biosciences ($10.8B) and Acceleron ($11.5B) to secure future drugs. In 2023, Merck took a $16.9B R&D charge related largely to these deals (writing off in-process R&D) (www.sec.gov), which cratered that year’s GAAP earnings. While these investments might pay off in new blockbusters, there is no guarantee – pipeline drugs can fail trials or underperform commercially. If Merck’s ambitious $70B sales pipeline falls short, the company could face a growth gap post-2028. Large acquisitions also carry risks of integration, high costs, or overpaying for uncertain results. Merck must execute nearly flawlessly on R&D to justify its massive pipeline outlays.

- Pricing and Regulatory Pressure – The pharmaceutical industry faces mounting pricing pressures, and Merck is no exception. The U.S. Inflation Reduction Act’s Medicare price negotiation program is set to target top-selling drugs. Merck expects Keytruda will be selected for Medicare price negotiation by 2026, with discounted pricing imposed by 2028 (www.sec.gov). In fact, Merck has filed a lawsuit challenging this policy (www.sec.gov), reflecting how serious the impact could be. Additionally, outside the U.S., many health systems push back on high drug prices (for instance, Japan already forced a 17.5% price cut on Keytruda in 2020). Global pricing reforms and austerity measures are a risk to Merck’s profit margins on its drugs, especially as governments try to rein in healthcare costs.

- Competition in Oncology – While Keytruda currently dominates the immuno-oncology market, competition is growing. Rival PD-(L)1 inhibitors like Bristol Myers Squibb’s Opdivo, Roche’s Tecentriq, and GSK’s Jemperli are vying for similar cancer indications. In endometrial cancer, for example, GSK’s Jemperli is seeking to expand its label after Keytruda’s broad approval (www.fiercepharma.com). Elsewhere, novel therapies (CAR-T cell therapies, bispecific antibodies, etc.) are emerging in cancer care. There is a risk that newer treatments could displace or reduce the use of Keytruda in certain settings over time. Merck will need to continuously innovate (e.g. combine Keytruda with other agents, develop new formulations like the subcutaneous Keytruda recently approved in 2025 (www.fiercepharma.com) (www.nasdaq.com)) to defend its turf. The oncology landscape can shift quickly, and sustaining leadership is not guaranteed.

- One-Time Charges and Accounting Noise – Merck’s financials can exhibit volatility due to large one-time items. As noted, 2023 earnings were unusually low because of hefty acquisition-related charges (www.sec.gov). These kinds of impacts (impairments, write-offs, legal charges, etc.) can muddy the true earnings trend and might concern some investors. While Merck’s core recurring earnings and cash flow are strong, such charges are a reminder of the cost of doing business in pharma – high upfront R&D spending with uncertain payoff. There is some execution risk that heavy investment today may not yield proportional returns tomorrow.

Overall, the key risk is that Merck’s golden goose (Keytruda) faces an unavoidable decline in a few years, and it’s uncertain if the next generation of products will be ready in time to fully compensate. Any delays, disappointments, or external pressures could weigh heavily on the company’s financial outlook.

Open Questions

Finally, here are some open questions and wildcards that investors may be contemplating as Merck moves forward:

- Can Merck replace Keytruda’s revenue? The company projects over $70B in new annual revenue by the mid-2030s from its pipeline and recent acquisitions (www.fiercepharma.com). Is this realistic? Merck will need multiple blockbusters to emerge (in oncology and other areas) to even approach that figure. Investors will be watching the clinical trial results over the next few years to see if Merck’s confidence is well-founded (www.fiercepharma.com).

- Will Keytruda’s exclusivity be extended or effectively prolonged? Merck is attempting life-cycle management moves like a subcutaneous formulation of Keytruda (approved in late 2025) to potentially secure additional patent protection (www.nasdaq.com). It also has secondary patents that could push LOE to 2029 (www.fiercepharma.com). How successful will these efforts be in fending off biosimilars? Even an extra year of exclusivity for a ~$35B/year drug is enormously valuable – but it could come down to legal battles and negotiating with generic challengers.

- What is the plan for Animal Health? Merck’s Animal Health division (which had about $5.9B sales in 2024 (www.sec.gov)) is a steady growth business that diversifies the company. Some peers have spun off or separated such businesses to unlock value. Will Merck consider an Animal Health spin-off or keep it integrated for its stable cash flows? The decision could have implications for Merck’s growth profile and shareholder value creation strategy.

- Will Merck keep making big acquisitions? With looming patent cliffs, pharma giants often turn to M&A. Merck has been active – e.g. buying Acceleron, Prometheus, and most recently Verona Pharma (announced 2025) – to boost its pipeline (www.stocksfoundry.com). The company still has a strong balance sheet and cash flow to deploy. Investors are asking: Will further large deals be on the menu? Significant acquisitions could accelerate growth but might also increase debt or dilute the focus on internal R&D. How Merck balances organic innovation versus buying growth remains an open question.

- Can the dividend stay safe and growing post-2028? Merck’s dividend is well-funded now, but when Keytruda sales decline after LOE, there could be a temporary hit to earnings and cash flow. Will Merck be able to maintain its dividend growth streak through the patent cliff period? The answer will depend on how smoothly new products ramp up and how the company manages costs. Thus far, Merck’s management has expressed confidence that it can navigate 2028–2030 “without a meaningful degradation” in earnings (www.stocksfoundry.com), which bodes well for sustaining shareholder returns – but this will be a critical area to monitor.

Merck’s recent FDA win for Keytruda is undoubtedly a big opportunity to cement its oncology dominance in the near term. The company’s challenge is to capitalize on such wins while also preparing for the future. How Merck executes in the next 2–3 years – advancing its pipeline, managing its portfolio, and strategizing for life after Keytruda – will determine whether this stock realizes the significant upside that a successful transition could entail, or struggles under the weight of its looming patent expirations. The stakes are high, and investors will be watching each development closely.